The chemerin receptor 23 agonist, chemerin, attenuates monosynaptic C-fibre input to lamina I neurokinin 1 receptor expressing rat spinal cord neurons in inflammatory pain

Mol Pain. 2014 Apr 9:10:24. doi: 10.1186/1744-8069-10-24.

Abstract

Background: Recent evidence has shown that the chemerin receptor 23 (ChemR23) represents a novel inflammatory pain target, whereby the ChemR23 agonists, resolvin E1 and chemerin, can inhibit inflammatory pain hypersensitivity, by a mechanism that involves normalisation of potentiated spinal cord responses. This study has examined the ability of the ChemR23 agonist, chemerin, to modulate synaptic input to lamina I neurokinin 1 receptor expressing (NK1R+) dorsal horn neurons, which are known to be crucial for the manifestation of inflammatory pain.

Results: Whole-cell patch-clamp recordings from pre-identified lamina I NK1R+ neurons, in rat spinal cord slices, revealed that chemerin significantly attenuates capsaicin potentiation of miniature excitatory postsynaptic current (mEPSC) frequency, but is without effect in non-potentiated conditions. In tissue isolated from complete Freund's adjuvant (CFA) treated rats, chemerin significantly reduced the peak amplitude of monosynaptic C-fibre evoked excitatory postsynaptic currents (eEPSCs) in a subset of lamina I NK1R+ neurons, termed chemerin responders. However, chemerin did not alter the peak amplitude of monosynaptic C-fibre eEPSCs in control tissue. Furthermore, paired-pulse recordings in CFA tissue demonstrated that chemerin significantly reduced paired-pulse depression in the subset of neurons classified as chemerin responders, but was without effect in non-responders, indicating that chemerin acts presynaptically to attenuate monosynaptic C-fibre input to a subset of lamina I NK1R+ neurons.

Conclusions: These results suggest that the reported ability of ChemR23 agonists to attenuate inflammatory pain hypersensitivity may in part be due to a presynaptic inhibition of monosynaptic C-fibre input to lamina I NK1R+ neurons and provides further evidence that ChemR23 represents a promising inflammatory pain target.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials / drug effects
  • Adipokines / pharmacology
  • Adipokines / therapeutic use*
  • Animals
  • Capsaicin / toxicity
  • Chemokines
  • Disease Models, Animal
  • Electric Stimulation
  • Excitatory Postsynaptic Potentials / drug effects
  • Female
  • Freund's Adjuvant / toxicity
  • In Vitro Techniques
  • Inflammation / chemically induced
  • Inflammation / complications
  • Intercellular Signaling Peptides and Proteins
  • Male
  • Nerve Fibers, Unmyelinated / drug effects
  • Nerve Fibers, Unmyelinated / physiology*
  • Neurons / drug effects
  • Neurons / physiology*
  • Pain / drug therapy*
  • Pain / etiology
  • Rats
  • Rats, Sprague-Dawley
  • Reaction Time / drug effects
  • Receptors, Neurokinin-1 / metabolism*
  • Spinal Cord / cytology*
  • Spinal Cord / drug effects
  • Spinal Cord / metabolism

Substances

  • Adipokines
  • Chemokines
  • Intercellular Signaling Peptides and Proteins
  • Rarres2 protein, rat
  • Receptors, Neurokinin-1
  • Freund's Adjuvant
  • Capsaicin